Fiera Capital Corp Acquires 2,610 Shares of PROCEPT BioRobotics Corporation $PRCT

Fiera Capital Corp grew its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 1.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 218,678 shares of the company’s stock after purchasing an additional 2,610 shares during the period. Fiera Capital Corp owned about 0.40% of PROCEPT BioRobotics worth $12,596,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Osterweis Capital Management Inc. lifted its position in PROCEPT BioRobotics by 98.0% during the 1st quarter. Osterweis Capital Management Inc. now owns 173,735 shares of the company’s stock worth $10,122,000 after buying an additional 85,990 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in shares of PROCEPT BioRobotics in the second quarter valued at about $2,532,000. Millennium Management LLC raised its holdings in PROCEPT BioRobotics by 88.6% during the first quarter. Millennium Management LLC now owns 542,987 shares of the company’s stock worth $31,634,000 after acquiring an additional 255,140 shares in the last quarter. Blair William & Co. IL boosted its position in PROCEPT BioRobotics by 5.7% during the second quarter. Blair William & Co. IL now owns 497,205 shares of the company’s stock valued at $28,639,000 after purchasing an additional 26,919 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in PROCEPT BioRobotics in the first quarter valued at approximately $2,913,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

Analyst Upgrades and Downgrades

PRCT has been the topic of several recent analyst reports. Truist Financial dropped their price objective on PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Piper Sandler restated an “overweight” rating and set a $50.00 target price (down from $55.00) on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company dropped their target price on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $59.78.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $30.42 on Friday. The company’s 50-day moving average is $35.37 and its 200-day moving average is $47.04. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The firm has a market capitalization of $1.70 billion, a PE ratio of -19.88 and a beta of 0.98. PROCEPT BioRobotics Corporation has a fifty-two week low of $29.78 and a fifty-two week high of $100.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. The business had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. PROCEPT BioRobotics’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) EPS. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).